{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,11]],"date-time":"2025-05-11T00:00:45Z","timestamp":1746921645790,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12328-024-01947-6","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T05:01:56Z","timestamp":1710997316000},"page":"523-529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Two cases of severe oral mucositis caused by atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Yasuharu","family":"Shimoji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3632-8326","authenticated-orcid":false,"given":"Ryo","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Fukunaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhide","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Shakado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihito","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"1947_CR1","doi-asserted-by":"crossref","unstructured":"Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808\u201320.","DOI":"10.1016\/S1470-2045(20)30156-X"},{"key":"1947_CR2","doi-asserted-by":"crossref","unstructured":"Finn RS, Qin S, Ikeda M, et al. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","DOI":"10.1056\/NEJMoa1915745"},{"key":"1947_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.6004\/jnccn.2020.7697","volume":"19","author":"JS Jacob","year":"2021","unstructured":"Jacob JS, Dutra BE, Garcia-Rodriguez V, et al. Clinical characteristics and outcomes of oral mucositis associated with immune checkpoint inhibitors in patients with cancer. J Natl Compr Canc Netw. 2021;19:1415\u201324.","journal-title":"J Natl Compr Canc Netw"},{"key":"1947_CR4","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1038\/s41388-020-1249-9","volume":"39","author":"DJ Pinato","year":"2020","unstructured":"Pinato DJ, Guerra N, Fessas P, et al. Immune-based therapies for hepatocellular carcinoma. Oncogene. 2020;39:3620\u201337.","journal-title":"Oncogene"},{"key":"1947_CR5","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","volume":"6","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6:865\u201371.","journal-title":"JAMA Oncol"},{"key":"1947_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.768957","volume":"12","author":"H Westdorp","year":"2021","unstructured":"Westdorp H, Sweep MWD, Gorris MAJ, et al. Mechanisms of immune checkpoint inhibitor-mediated colitis. Front Immunol. 2021;12: 768957.","journal-title":"Front Immunol"},{"key":"1947_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0332-z","volume":"6","author":"FZ Acero Brand","year":"2018","unstructured":"Acero Brand FZ, Suter N, Adam JP, et al. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. J Immunother Cancer. 2018;6:1\u20135.","journal-title":"J Immunother Cancer"},{"key":"1947_CR8","doi-asserted-by":"publisher","first-page":"604","DOI":"10.4103\/apjon.apjon-2136","volume":"8","author":"MF Asan","year":"2021","unstructured":"Asan MF, Castelino RL, Babu SG, et al. Oral immune-related adverse events\u2014current concepts and their management. Asia Pac J Oncol Nurs. 2021;8:604\u20139.","journal-title":"Asia Pac J Oncol Nurs"},{"key":"1947_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00520-017-3629-4","volume":"25","author":"E Vigarios","year":"2017","unstructured":"Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25:1713\u201339.","journal-title":"Support Care Cancer"},{"key":"1947_CR10","doi-asserted-by":"crossref","unstructured":"Zhu AX, Finn RS, Edeline J, et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940\u201352.","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"1947_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2014.06.005","volume":"53","author":"N Okiyama","year":"2014","unstructured":"Okiyama N, Katz SI. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes. J Autoimmun. 2014;53:1\u20139.","journal-title":"J Autoimmun"},{"key":"1947_CR12","doi-asserted-by":"publisher","first-page":"1109281","DOI":"10.3389\/fimmu.2023.1109281","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Tang H, Zhou Q, et al. Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events. Front Immunol. 2023;14:1109281.","journal-title":"Front Immunol"},{"key":"1947_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/cup.12876","volume":"44","author":"KL Vivar","year":"2017","unstructured":"Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44:381\u20134.","journal-title":"J Cutan Pathol"},{"key":"1947_CR14","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1158\/1078-0432.CCR-15-2872","volume":"22","author":"SM Goldinger","year":"2016","unstructured":"Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22:4023\u20139.","journal-title":"Clin Cancer Res"},{"key":"1947_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13046-020-01715-7","volume":"39","author":"C Pulito","year":"2020","unstructured":"Pulito C, Cristaudo A, Porta CL, et al. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020;39:210.","journal-title":"J Exp Clin Cancer Res"},{"issue":"27","key":"1947_CR16","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.4317\/medoral.25253","volume":"1","author":"JO Martins","year":"2022","unstructured":"Martins JO, Borges MM, Malta CE, Carlos AC, Crispim AA, Moura JF, Fernandes-Lima IJ, Silva PG. Risk factors for oral mucositis during chemotherapy treatment for solid tumors: a retrospective STROBE-guided study. Med Oral Patol Oral Cir Bucal. 2022;1(27):e319-329.","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"1947_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.bulcan.2018.07.005","volume":"105","author":"T Passat","year":"2018","unstructured":"Passat T, Touchefeu Y, Gervois N, et al. Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment. Bull Cancer. 2018;105:1033\u201341.","journal-title":"Bull Cancer"},{"key":"1947_CR18","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1093\/oncolo\/oyad090","volume":"28","author":"T Fukushima","year":"2023","unstructured":"Fukushima T, Morimoto M, Kobayashi S, et al. Association between immune-related adverse events and survival in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab. Oncologist. 2023;28:e526-533.","journal-title":"Oncologist"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-024-01947-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-024-01947-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-024-01947-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T13:13:18Z","timestamp":1716642798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-024-01947-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,21]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1007\/s12328-024-01947-6","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"type":"print","value":"1865-7257"},{"type":"electronic","value":"1865-7265"}],"subject":[],"published":{"date-parts":[[2024,3,21]]},"assertion":[{"value":"25 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Done.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}